Prelude Capital Management, LLC Supernus Pharmaceuticals, Inc. Transaction History

Prelude Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $18,514 - $26,997	-1,046 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$20.2 - $25.05 $52,439 - $65,029	-2,596 Reduced 71.28%	1,046 $22,000
Q2 2020 Aug 14, 2020	BUY	$17.09 - $24.89 $11,860 - $17,273	694 Added 23.54%	3,642 $86,000
Q4 2018 Feb 14, 2019	SELL	$30.84 - $49.51 $213,166 - $342,213	-6,912 Reduced 70.1%	2,948 $98,000
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $12,612 - $17,117	286 Added 2.99%	9,860 $590,000
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $29,720 - $37,520	800 Added 9.12%	9,574 $438,000
Q4 2017 Feb 14, 2018	BUY	$36.4 - $42.6 $83,574 - $97,809	2,296 Added 35.44%	8,774 $350,000
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $238,066 - $321,632	6,478	6,478 $259,000

267

59.7M

47.9K

13.1K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.96B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.